Leebarooski
4 years ago
Looks good. On June 1, 2020, the Company announced that its Board of Directors has determined that the Amended Melinta Proposal to acquire the Company is a “Superior Offer” under the terms of the AcelRx Merger Agreement. In connection with this determination and in accordance with the terms of the AcelRx Merger Agreement, the Company has given notice to AcelRx of such determination and of its intention to consider changing its recommendation of the AcelRx Merger Agreement or terminating the AcelRx Merger Agreement unless AcelRx proposes revisions to the terms of the AcelRx Merger Agreement or makes another proposal on or prior to Wednesday, June 3, 2020 that, if accepted, would result in the Amended Melinta Proposal ceasing to be a Superior Offer. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. TTPH
BuyOnDips
4 years ago
TTPH—(+69%/AH)—receives unsolicited buyout offer from LJPC that trumps ACRX’s buyout deal announced on 3/16/20 (#msg-154357912):
https://www.sec.gov/Archives/edgar/data/920465/000092046520000067/exhibitfy20tetraphase.htm
Quote:
On behalf of La Jolla Pharmaceutical Company, I am pleased to submit this non-binding proposal to acquire 100% of the equity of Tetraphase Pharmaceuticals, Inc. for $22 million in cash plus an additional $12.5 million potentially payable under CVRs to be issued in the transaction. The $22 million upfront consideration would include amounts payable under the Black-Scholes put provisions in Tetraphase’s outstanding warrants and be subject to a minimum, to-be-agreed-upon closing net cash balance.
The terms of the CVRs would match those set forth in Tetraphase’s merger agreement with AcelRx Pharmaceuticals, Inc., except that payments pursuant to the CVRs would be made in cash instead of cash or stock at the acquiror’s option.
rusty8350
4 years ago
Several promising known drugs stand out as potential inhibitors of SARS-Cov-2 main protease, including Carfilzomib, Eravacycline, Valrubicin, Lopinavir and Elbasvir. Carfilzomib, an approved anti-cancer drug acting as a proteasome inhibitor, has the best MM-PBSA-WSAS binding free energy, -13.8 kcal/mol. The second-best repurposing drug candidate, eravacycline, is synthetic halogenated tetracycline class antibiotic.
https://pubs.acs.org/doi/10.1021/acs.jcim.0c00179
XenaLives
4 years ago
This one's getting carved up by the Big Boys..
2020-01-31 13G INTRACOASTAL CAPITAL, LLC 725,657 9.40
2020-01-31 13G CVI Investments, Inc. 666,666 9.40
2020-01-28 13G Sabby Management, LLC 666,667 9.37
2020-01-23 13D ARMISTICE CAPITAL, LLC 1,419,507 19.90
2019-07-10 13G/A BlackRock Inc. 1,267,370 2.30
2019-01-30 13G/A INTEGRATED CORE STRATEGIES (US) LLC 11,409 0.00
https://fintel.io/so/us/ttph